What Altimmune, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 1 | 11 |
| Sells | 0 | 0 |
| Total trades | 9 | 44 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 44 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Arbet-Engels Christophe | Chief Medical Officer | Oct 01 | Withheld — tax / exercise cost · F | −12,679 | $2.76 | −$35K | 24,821 |
| Arbet-Engels Christophe | Chief Medical Officer | Oct 01 | Exercise / conversion · M | +37,500 | — | — | 37,500 |
| Weaver Gregory L | Chief Financial Officer | Oct 01 | Withheld — tax / exercise cost · F | −4,379 | $2.76 | −$12.1K | 49,927 |
| Weaver Gregory L | Chief Financial Officer | Oct 01 | Exercise / conversion · M | +14,475 | — | — | 54,306 |
| Richardson Linda M | Chief Commercial Officer | Sep 16 | Withheld — tax / exercise cost · F | −6,826 | $3.24 | −$22.1K | 17,174 |
| Richardson Linda M | Chief Commercial Officer | Sep 16 | Exercise / conversion · M | +24,000 | — | — | 24,000 |
| Durso Jerome Benedict | President and CEO | Aug 13 | Open-market buy · P | +15,000 | $2.95 | +$44.3K | 62,500 |
| Weaver Gregory L | Chief Financial Officer | Jul 31 | Grant / award · A | +1,753 | $2.41 | +$4.23K | 39,831 |
| Roberts M Scot | Chief Scientific Officer | Jul 31 | Grant / award · A | +875 | $2.41 | +$2.11K | 113,699 |
| Gill John | Director | Apr 06 | Open-market buy · P | +9,200 | $3.41 | +$31.3K | 21,700 |
| Durso Jerome Benedict | President and CEO | Apr 01 | Open-market buy · P | +15,000 | $3.14 | +$47.1K | 47,500 |
| Weaver Gregory L | Chief Financial Officer | Apr 01 | Open-market buy · P | +10,000 | $3.15 | +$31.5K | 38,078 |
| Durso Jerome Benedict | President and CEO | Mar 06 | Open-market buy · P | +20,000 | $3.54 | +$70.8K | 32,500 |
| Weaver Gregory L | Chief Financial Officer | Mar 06 | Open-market buy · P | +5,000 | $3.54 | +$17.7K | 28,078 |
| Roberts M Scot | Chief Scientific Officer | Feb 02 | Withheld — tax / exercise cost · F | −2,329 | $5.55 | −$12.9K | 112,824 |
| Roberts M Scot | Chief Scientific Officer | Feb 02 | Exercise / conversion · M | +7,775 | — | — | 115,153 |
| Roberts M Scot | Chief Scientific Officer | Jan 31 | Grant / award · A | +5,567 | $3.07 | +$17.1K | 107,378 |
| Jordt Raymond M | Chief Business Officer | Jan 31 | Grant / award · A | +4,571 | $3.07 | +$14K | 70,107 |
| Garg Vipin K | Director | Jan 31 | Grant / award · A | +6,926 | $3.07 | +$21.3K | 424,519 |
| Roberts M Scot | Chief Scientific Officer | Jan 30 | Withheld — tax / exercise cost · F | −2,859 | $5.60 | −$16K | 101,811 |
Loading...
